Skip to search formSkip to main contentSkip to account menu

ONC201

Known as: Akt/ERK Inhibitor ONC201 
A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

TIC10 compound

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
2563Background: High-grade gliomas of the spinal cord are a rare and understudied entity, representing < 5% of all spinal cord… 
2020
2020
Phase II study of ONC201 in pheochromocytoma-paragangliomas (PC-PG), medullary thyroid carcinoma (MTC), and other neuroendocrine tumors.
e16703Background: ONC201 is an imipridone with specificity for the dopamine-like DRD2 receptor. Anti-cancer effects involve up… 
2019
2019
Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic
ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor related apoptosis inducing ligand… 
2018
2018
Abstract 2933: Synergistic antitumor effect of ONC201 in combination with radiation therapy
Radiation therapy is used as the main treatment when surgery is not feasible, before/after surgery, and to palliate symptoms in… 
2018
2018
Intratumoral activity of ONC201 in adult recurrent glioblastoma patients.
e14034Background: ONC201 is an antagonist of the G protein-coupled receptor DRD2 that crosses the blood-brain barrier and induces… 
2017
2017
Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway
ONC201 is the lead small molecule of the imipridone class of anti-cancer compounds that is currently being evaluated in phase I… 
2016
2016
Abstract 3062: Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy
Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer… 
2015
2015
First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
TPS2623 Background: ONC201 is an orally active first-in-class small molecule with strong antitumor activity in preclinical models… 
2015
2015
A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
High-dose methylprednisolone (HDMP) and rituximab (R) is an effective non-myelosuppressive treatment regimen for patients (pts… 
2014
2014
ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition
ONC201 is a novel agent with profound anti-tumor effects, reported to induce p53-independent apoptosis in diverse types of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)